Cancer Home > Aranesp and Breastfeeding
Since no studies have been conducted on Aranesp and breastfeeding, it is not known whether the drug passes through breast milk in humans. Aranesp is a protein that can be destroyed by the digestive system, however, which means that it is not likely to cause problems in a nursing infant even if it does pass through breast milk.
Aranesp® (darbepoetin alfa) is a medication used for the treatment of anemia due to chemotherapy or chronic kidney failure (renal failure). At this time, it is not known whether Aranesp passes through breast milk. Therefore, if you are breastfeeding or thinking of starting, make sure to let your healthcare provider know.
Aranesp has not been studied in any breastfeeding women, and it is not known whether it passes through breast milk. Theoretically, Aranesp would probably not cause any problems in breastfed infants. The medication is a protein that must be given by injection, since the digestive system would destroy the protein. If Aranesp passes through breast milk, it would be digested (and destroyed) in the digestive systems of breastfed infants.
You should talk with your healthcare provider about Aranesp and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, you and your healthcare provider can make a shared decision about Aranesp and breastfeeding in your particular situation.